Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer

Reuters12-09

Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

SeekingHuat
12-09
SeekingHuat
你c

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590207313?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 15:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590207313","market":"us","top_or_hot":-1,"title":"Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 15:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BPRC5H50.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8xVxf1:1","article_id":"2590207313","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590207313","pubTimestamp":1765266685,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akeso Inc. announced results from a Phase II clinical study  evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response  rate was 28.6%, and the major pathologic response  rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial  of cadonilimab combined with SOX for perioperative treatment in this patient population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","09926":"康方生物","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1574":"生物医药B类股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD"},"translate_title":"康方生物报告卡多尼单抗可切除胃癌II期研究R0切除率100%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    \n\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":508935438774552,"gmtCreate":1765283325620,"gmtModify":1765286103848,"author":{"id":"4105714002486270","authorId":"4105714002486270","name":"SeekingHuat","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"4105714002486270","authorIdStr":"4105714002486270"},"htmlText":"你c","listText":"你c","text":"你c","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/508935438774552","repostId":2590207313,"repostType":2,"repost":{"id":"2590207313","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1765266685,"share":"https://ttm.financial/m/news/2590207313?lang=en_US&edition=fundamental","pubTime":"2025-12-09 15:51","market":"us","language":"en","title":"Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590207313","media":"Reuters","summary":"Akeso Inc. announced results from a Phase II clinical study  evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response  rate was 28.6%, and the major pathologic response  rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial  of cadonilimab combined with SOX for perioperative treatment in this patient population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 15:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","09926":"康方生物","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1574":"生物医药B类股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8xVxf1:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2590207313","content_text":"Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer\n    \n\n        Akeso Inc. announced results from a Phase II clinical study (COMPASSION-25) evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response (pCR) rate was 28.6%, and the major pathologic response (MPR) rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial (AK104-310/COMPASSION-33) of cadonilimab combined with SOX for perioperative treatment in this patient population.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42347) on December 09, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"09926":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590207313","isCrawlerRequest":true}